Whalesbook
Global Health Limited (Medanta) finished fiscal year 2026 with a strong fourth quarter. Revenue jumped 25% to ₹1,159 crore, while profit after tax climbed 42% to ₹144 crore, a healthy 12.4% profit margin. This growth is backed by ambitious expansion plans, including adding around 2,700 beds over the next three to four years through five new projects.
Noida Hospital Shows Progress Towards Breakeven
Medanta's new Noida hospital is a key part of its growth strategy. Although it posted an EBITDA loss of ₹23.6 crore in Q4 FY26, this loss decreased from the prior quarter, showing better usage. Management expects the hospital to reach breakeven by the second half of FY27, a crucial step for overall profits. Excluding Noida, Medanta's other new hospitals saw strong 29% revenue growth. Its established hospitals in Gurugram, Indore, and Ranchi grew revenue by 9%, maintaining stable EBITDA margins around 24.4%.
Ambitious Expansion Meets Premium Valuation
Medanta plans to add about 500 beds in existing sites soon and develop 2,700 beds across five new greenfield projects, including sites in Varanasi and Guwahati. The company ended FY26 with a net cash of ₹590 crore and operating cash flow of ₹714 crore. However, Medanta's current valuation is high. It trades at a Price-to-Earnings (P/E) ratio of 54-64 times earnings, higher than the Indian healthcare industry average of about 40x. It is valued similarly to peers like Apollo Hospitals (P/E ~63.87x) and Fortis Healthcare (P/E ~75x). Medanta's projected annual revenue growth of 12% for the next two years is also below the industry's estimated 20%.
Key Risks: Execution, Competition, and Regulations
Despite strong results, risks remain. Successfully making the Noida facility profitable is crucial, and delays could hurt financial forecasts. Executing the large greenfield expansion demands significant investment and careful management to avoid cost overruns or delays. Medanta faces tough competition from Apollo Hospitals and Fortis Healthcare, who are also expanding. The healthcare sector also faces evolving regulations, such as potential price controls that could impact revenue. Investor sentiment has been sensitive to changes in analyst forecasts, causing stock drops in the past. Medanta's promoter holding of 33.01% (as of Sept 2025) might also be a point some investors watch for corporate governance.
Outlook: Analyst Views and Growth Drivers
Looking ahead, management expects FY27 growth to come from the Noida hospital improving, new beds being added, and increased operational capacity. Analysts are generally positive, with price targets suggesting modest potential upside. The average 1-year price target for Medanta is about ₹1,309.99, a potential 4% increase. While recent analyst estimates have been stable, some earlier reports had lowered revenue and earnings per share (EPS) forecasts. Medanta's success will depend on executing its expansion plans, managing competition, and maintaining profitability. The overall healthcare sector is expected to grow well, helped by greater health awareness and government support.